[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Guangzhou Burning Rock Dx Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100456741","multi-cancer-early-detection-test-in-asymptomatic-individuals-prevent-100456741",false,"NCT05227534","Multi-canceR Early-detection Test in Asymptomatic Individuals (PREVENT)","A Prospective Multi-canceR Early-detection and interVENTional Study in Asymptomatic Individuals: PREVENT","PREVENT","Inclusion Criteria:\n\n* Participants must be able to provide a written informed consent form\n* Participants must not have received any colonoscopy, abdominal MRI\u002FCT, low-dose CT, or chest CT within 5 years before signing the informed consent form\n* Participants must be able to provide blood samples for study tests\n* Participants must be between 40 and 75 years old\n\nExclusion Criteria:\n\n* Individuals who have an acute infection or inflammation within 14 days prior to recruitment\n* Individuals with cancer-associated clinical symptoms or suspected of cancer\n* Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant\n* Recipient of blood transfusion within 7 days prior to recruitment\n* Individuals who have pure ground-glass opacity\n* Unable to provide blood samples for the multi-cancer early detection blood test\n* Individuals who are unable to tolerate standard-of-care cancer screening tests or have contraindications of standard-of-care cancer screening tests\n* Individuals who have taken medication with anti-tumor effects within 30 days prior to recruitment\n* Individuals who have received or are undergoing curative cancer treatment within three years prior to recruitment\n* Individuals with hemorrhagic diseases\n* Individuals with autoimmune diseases\n* Individuals who are pregnant or lactating\n* Individuals who have severe comorbidities that are not suitable for participating in the trial judged by researchers",true,"ALL","40 Years","75 Years",{"count":22,"type":23},12500,"ESTIMATED","INTERVENTIONAL",[26],"NA","PREVENT is a prospective, multicenter, interventional study evaluating the performance of the OverC multi-cancer detection blood test in asymptomatic individuals with cancer risk.",[29,30,31],"Cancer","Early Detection of Cancer","Circulating Cell-free DNA","RECRUITING","2022-06-30",{"date":35,"type":36},"2022-07-06","ACTUAL",{"date":38,"type":36},"2022-06-01",{"date":40,"type":23},"2028-12-31",{"name":42,"class":43},"Guangzhou Burning Rock Dx Co., Ltd.","INDUSTRY",""]